Index

Note: Page numbers of article titles are in boldface type.

A
Acetaminophen
in pain management in the elderly, 340
Acute incontinence, 408–409
Advance care planning
described, 392–393
in the elderly, 391–403
benefits of, 393–395
clinician and health care system barriers to, 395–396
introduction, 391–392
key concepts in, 396–399
asking about values related to quality of care, 398
assessing patient readiness and identifying barriers, 396–397
documenting preferences, 398–399
identifying surrogate decision makers, 397–398
translating preferences into medical care plans, 399
need for, 393–396
new patient-centered tools in, 400–401
special considerations for, 399
team-based approaches to, 399–400
Aging
of “baby boomers,” 379
Analgesia/analgesics
nonopioid
in pain management in the elderly, 346–347
Anticoagulant(s)
oral
in AF management in the elderly, 417–430. See also Atrial fibrillation (AF), in the elderly, management of
Antiplatelet therapy
in AF management in the elderly, 423–424
Antithrombotic therapy
in AF management in the elderly, 417–430. See also Atrial fibrillation (AF), in the elderly, management of
Apnea
sleep
in the elderly, 432–433
Aspirin
in AF management in the elderly, 423
Atrial fibrillation (AF)

http://dx.doi.org/10.1016/S0025-7125(15)00012-7
medical.theclinics.com
0025-7125/15/$ – see front matter © 2015 Elsevier Inc. All rights reserved.
Atrial (continued)
in the elderly
  management of
    antithrombotics in, 417–430
    bleeding risk assessment in, 420–421
    future considerations in, 427
    goals in, 418–421
    pharmacologic strategies in, 421–427
      antiplatelet therapy, 423–424
      non-vitamin D–dependent OACs, 424–427
      OACs with warfarin, 421–423
    stress risk assessment in, 418–420

B
“Baby boomers”
  aging of, 379
Balance exercises
  in fall risk management in older adults, 287–288
Blood pressure control. See also Hypertension
  in diabetes management in the elderly, 371
  outcomes related to, 382–384
Breast cancer screening
  in the elderly
    evidence for, 252

C
Calcium channel blockers
  drug interaction with
    in older adults, 301–302
Cancer screening
  current practices, 250
  in the elderly
    evidence for, 250–254
      breast cancer screening, 252
      cervical cancer screening, 253–254
      colorectal cancer, 250–252
      lung cancer screening, 252–253
      prostate cancer screening, 253
    estimating life expectancy by, 254
    practical approach to, 255–258
    what do patients want, 254
    when to stop, 249–262
Capsaicin
  topical, 347
Cervical cancer screening
  in the elderly
    evidence for, 253–254
Cholinesterase inhibitors
  in cognitive complaints management in the elderly, 323–325
Cognitive complaints
in the elderly, 311–335
  evaluation of, 312–317
    cognitive testing in, 314
    diagnostic dilemmas in, 317
    imaging and additional testing in, 315–317
    neuropsychiatric symptoms in, 314–315
    patient history in, 312–313
    physical examination in, 314
  future considerations in, 328
  introduction, 311–312
  management of, 317–328
    end-of-life care in, 327–328
    evaluation, adjustment, and recurrence in, 327
    goals in, 317–319
    nonpharmacologic strategies in, 319–323
    pharmacologic strategies in, 323–326
      cholinesterase inhibitors, 323–325
      memantine, 325
      supplements and medical foods, 325–326
    pathophysiology of, 313–314
Cognitive impairment
  in the elderly
    assessment of, 269–270
Colorectal cancer screening
  in the elderly
    evidence for, 250–252

D
Dementia
  in the elderly
    management of, 317–319
      nonpharmacologic strategies in, 319–323
    neuropsychiatric symptoms of
      pharmacologic management of, 326
    fall risk management in patients with, 289
Diabetes
  in the elderly, 351–377
    incidence of, 352
    introduction, 351
    management of, 351–377
      blood pressure control in, 371
      evaluation and adjustment in, 370–372
      eye care in, 371
      foot care in, 371
      future considerations in, 372
      glycemic control in, 371
      goals in, 354–358
      lipid management in, 371
      medical nutrition therapy in, 369–370
      nonpharmacologic strategies in, 368–370
Diabetes (continued)
- pharmacologic strategies in, 354–355, 359–368
  - type 1 diabetes, 362–363
  - type 2 diabetes, 363–368
- physical activity in, 370
- renal function–related, 371
- self-management education and training in, 370
- overview of, 352–354
- prevalence of, 352

Drug–drug interactions
- in older adults, 295–310. See also Older adults, medications in, drug–drug interactions

Duloxetine
- in pain management in the elderly, 346

E

Elderly. See also Older adults
- advance care planning in, 391–403. See also Advance care planning, in the elderly
  - evidence for, 250–254. See also Cancer screening, in the elderly, evidence for
  - cognitive complaints in, 311–335. See also Cognitive complaints, in the elderly
  - diabetes in, 351–377. See also Diabetes, in the elderly
    - frail
      - in primary care, 264–266
      - urinary incontinence in, 413–414
    - functional status of, 264–266
    - medications in
      - side effects of, 302–303
- pain in
  - introduction, 337–338
  - pain management in, 337–350. See also Pain management, in the elderly
  - sleep problems in, 431–439. See also Sleep problems, in the elderly

End-of-life care
- in cognitive complaints management in the elderly, 327–328

Environmental assessment
- in fall risk assessment, 287

Eye care
- in diabetes management in the elderly, 371

F

Fall(s)
- in the elderly
  - assessment of, 267–269
- in primary care settings
  - defined, 281–282
  - magnitude of problem, 281–282
  - from older adults’ perspective, 282–283
  - risk factors for, 281–293
    - assessment of, 283–287. See also Fall risk assessment
    - introduction, 281–283
    - management of, 287–290
goals for older adults, 287–290. See also Older adults, fall risk management in

Fall risk assessment, 283–287
  clinical practice guideline in, 283
  environmental assessment in, 287
  fall-focused physical examination in, 286
  fall history in, 285
  functional assessment in, 286–287
  implementing screening and assessment in, 283–284
  laboratory tests and imaging in, 287
  medications in, 285
  postural hypotension in, 285–286

Foot care
  in diabetes management in the elderly, 371

Frail elderly
  in primary care, 264–266
  urinary incontinence in, 413–414

Frailty
  in the elderly
    assessment of, 271–272

Functional incontinence, 413

G

Gabapentin
  in pain management in the elderly, 346–347

Geriatric assessment, 263–279
  introduction, 263–264

Geriatric care systems
  examples of, 274–275
  future considerations in, 275–276
  innovative care delivery for complex patient, 272–275
    features of, 273–274
    vs. usual primary care needs, 272

Geriatric syndromes, 263–279
  assessment of, 263–279
    cognitive impairment, 269–270
    falls, 267–269
    frailty, 271–272
    future considerations in, 275–276
    practical approach to, 267–272
    urinary incontinence, 270–271
  described, 264–266
  introduction, 263–264

Glycemic control
  in older adults, 352–353
    in diabetes management, 371

H

Hypertension. See also Blood pressure control
  in older adults, 379–389
Index

Hypertension (continued)
  diagnostic considerations in, 382
  epidemiology of, 380
  introduction, 379–380
  management of
    current guidelines, 384–385
    nonpharmacologic strategies in, 385
    pharmacologic strategies in, 386
  pathophysiology of, 380–381
Hypoglycemia
  in older adults, 353
    risk factors, symptoms, and consequences of, 353–354
Hypotension
  postural
    in fall risk assessment, 285–286

I
Incontinence
  acute, 408–409
  functional, 413
  overflow, 413
  urgency, 411–412
  urinary, 405–416. See also Urinary incontinence
Insomnia
  in the elderly, 433–438
    described, 433–434
    diagnosis of, 434–435
    differential diagnosis of, 436–438
    treatment of, 435–436
      pharmacotherapy in, 436
      psychological interventions in, 435–436

L
Lidocaine
  topical
    in pain management in the elderly, 347–348
Lipid(s)
  management of
    in diabetes management in the elderly, 371
Lung cancer screening
  in the elderly
    evidence for, 252–253

M
Medical nutrition therapy
  in cognitive complaints management in the elderly, 325–326
  in diabetes management in the elderly, 369–370
Medication(s). See also specific drugs
in fall risk assessment, 285
in older adults, **295–310**

Memantine
in cognitive complaints management in the elderly, 325

**N**

Neuropsychiatric symptoms
in the elderly
management of
nonpharmacologic strategies in, 322–323

Non-vitamin D–dependent OACs
in AF management in the elderly, 424–427
described, 424–425
disadvantages of, 426–427
efficacy and safety of, 425–426

Nonopioid analgesics
in pain management in the elderly, 346–347

Nonsteroidal anti-inflammatory drugs (NSAIDs)
in pain management in the elderly, 340–341
topical
in pain management in the elderly, 347

NSAIDs. See Nonsteroidal anti-inflammatory drugs (NSAIDs)

O

OACs. See Oral anticogulants (OACs)

Occupational therapists
in fall risk management in older adults, 289

Older adults. See also Elderly
appropriate prescribing in, **295–310**
fall risk management in
address fall injury risk, 288
clinical approach to, 287–290
collaborate with patients and caregivers, 287
connect patients to evidence-based community fall prevention programs, 289
dementia patients, 289
discuss strength and balance exercises, 287–288
goals of, 287
involve relevant professional disciplines, 288–289
offer ongoing monitoring and follow-up, 289–290
prioritize interventions, 288
glycemic control in, 352–353
hypertension in, **379–389**. See also Hypertension, in older adults
hypoglycemia in, 353
risk factors, symptoms, and consequences of, 353–354
medications in
adherence to, 298–299
appropriate prescribing for
introduction, 295
drug–drug interactions, **295–310**
calcium channel blockers, 301–302
introduction, 295
Older (continued)
  overview, 299
  proton pump inhibitors, 301
  warfarin-related, 299–301
errors in, 298–299
high-risk and potentially inappropriate, 297–298
opportunities to stop, 304–305
polypharmacy, 296
  reducing, 303–307
side effects of, 302–303
  quinolones, 302–303
  SSRIs, 302
  trimethoprim-sulfamethoxazole, 303
multimorbidity among
  guidelines implications for, 297
  prevalence of, 295
Opioids
  in pain management in the elderly, 341–346
    black box warning related to, 345–346
    dosing of, 341–343
    drug selection, 341
    pharmacokinetics and pharmacodynamics of, 343–345
Oral anticoagulants (OACs)
  in AF management in the elderly, 417–430. See also Atrial fibrillation (AF), in the elderly, management of
    non-vitamin D–dependent
      in AF management in the elderly, 424–427. See also Non-vitamin D–dependent OACs, in AF management in the elderly
    warfarin with
      in AF management in the elderly, 421–423
Overflow incontinence, 413

P
Pain assessment
  in the elderly, 338–339
Pain management
  in the elderly, 337–350
    guidelines for, 339–340
    introduction, 337–338
    pain assessment in, 338–339
    pharmacologic, 340–348
      acetaminophen, 340
      nonopioid analgesics, 346–347
      NSAIDs, 340–341
      opioids, 341–346
      topical therapies, 347–348
Pelvic organ prolapse (POP), 405–407, 414
  classification of, 414
  evaluation of
    initial, 406–407
introduction, 405–406
treatment of, 414
Physical activity
in diabetes management in the elderly, 370
Physical therapists
in fall risk management in older adults, 288–289
Polypharmacy
in older adults, 296
  reducing, 303–307
    avoid prescribing cascade in, 304
    match drug regimens to patient conditions and goals of care in, 305–307
    medication review, 304
    opportunities to stop medications, 304–305
    overview, 303–304
POP. See Pelvic organ prolapse (POP)
Postural hypotension
  in fall risk assessment, 285–286
Pregabalin
  in pain management in the elderly, 346–347
Prescribing
  appropriate
    in older adults, 295–310. See also Older adults, medications in
Primary care settings
  fall risk in, 281–293. See also Fall(s), in primary care settings, risk factors for
Prostate cancer screening
  in the elderly
    evidence for, 253
Proton pump inhibitors
  drug interactions with
    in older adults, 301

Q
Quinolones
  side effects of
    in the elderly, 302–303

R
Renal function
  in diabetes management in the elderly, 371

S
Selective serotonin reuptake inhibitors (SSRIs)
  side effects of
    in the elderly, 302
Sleep apnea
  in the elderly, 432–433
Sleep problems
  in the elderly, 431–439
Sleep (continued)
    future considerations, 438
    insomnia, 433–438. See also Insomnia, in the elderly introduction, 431–432
    sleep apnea, 432–433
    types of, 431–432
SSRIs. See Selective serotonin reuptake inhibitors (SSRIs)
Strength
    in fall risk management in older adults, 287–288
Stress urinary incontinence (SUI), 409–410
    treatment of, 410
SUI. See Stress urinary incontinence (SUI)

T

Topical therapies
    in pain management in the elderly, 347–348
Trimethoprim-sulfamethoxazole
    side effects of
    in the elderly, 303

U

Urgency incontinence, 411–412
Urinary incontinence, 405–416
    acute, 408–409
    classification of, 407
    in the elderly
    assessment of, 270–271
    evaluation of
    initial, 406–407
    in the frail elderly, 413–414
    functional incontinence, 413
    introduction, 405–406
    overflow incontinence, 413
    SUI, 409–410
    treatment of, 410
    treatment of, 407
    urgency incontinence, 411–412

W

Warfarin
    drug interactions with
    in older adults, 299–301
OACs with
    in AF management in the elderly, 421–423